Last update June 10, 2018
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Inosine Dimepranol Acedoben is also known as
Inosine Dimepranol Acedoben in other languages or writings:
Inosine Dimepranol Acedoben belongs to this group or family:
Main tradenames from several countries containing Inosine Dimepranol Acedoben in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 90 | % |
Molecular weight | 1115 | daltons |
Tmax | 1 | hours |
T½ | 0.9 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A nucleoside derivative with antiviral properties. There is little published data on this product and little evidence of its efficacy as an antiviral (You 2015, Kinghorn 1992, Mindel 1989, Pachuta 1974) and even less as an immunostimulant (Smith 2015, Trentham 199).
It has been used with poor results in infections due to herpes simplex, genital warts, colds, subacute sclerosing panencephalitis, chronic fatigue syndrome and rheumatoid arthritis.
Administered orally every 4 to 6 hours for 2 to 4 weeks.
Since the last update we have not found published data on its excretion in breastmilk.
The little known pharmacokinetic data (high molecular weight and short half-life) make transfer to milk in significant amounts unlikely.
The manufacturer indicates its use in children, even from the first month of life. Possible side effects are usually mild and infrequent.
As there is less published information than for other drugs from the same group, safer known alternatives may be preferable during the neonatal period and in case of prematurity.